238 related articles for article (PubMed ID: 33434183)
1. Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner.
Jepsen SL; Albrechtsen NJW; Windeløv JA; Galsgaard KD; Hunt JE; Farb TB; Kissow H; Pedersen J; Deacon CF; Martin RE; Holst JJ
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434183
[TBL] [Abstract][Full Text] [Related]
2. Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice.
Jepsen SL; Grunddal KV; Wewer Albrechtsen NJ; Engelstoft MS; Gabe MBN; Jensen EP; Ørskov C; Poulsen SS; Rosenkilde MM; Pedersen J; Gribble FM; Reimann F; Deacon CF; Schwartz TW; Christ AD; Martin RE; Holst JJ
Am J Physiol Endocrinol Metab; 2019 Dec; 317(6):E1081-E1093. PubMed ID: 31503512
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Endogenous (Male) Rodent GLP-1 Secretion and Human Islet Insulin Secretion by Antagonism of Somatostatin Receptor 5.
Farb TB; Adeva M; Beauchamp TJ; Cabrera O; Coates DA; Meredith TD; Droz BA; Efanov A; Ficorilli JV; Gackenheimer SL; Martinez-Grau MA; Molero V; Ruano G; Statnick MA; Suter TM; Syed SK; Toledo MA; Willard FS; Zhou X; Bokvist KB; Barrett DG
Endocrinology; 2017 Nov; 158(11):3859-3873. PubMed ID: 28938487
[TBL] [Abstract][Full Text] [Related]
5. Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.
Esser N; Barrow BM; Choung E; Shen NJ; Zraika S
Islets; 2018; 10(5):175-180. PubMed ID: 30142012
[TBL] [Abstract][Full Text] [Related]
6. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
7. Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic islets.
Svendsen B; Holst JJ
Diabetologia; 2021 Jan; 64(1):142-151. PubMed ID: 33043402
[TBL] [Abstract][Full Text] [Related]
8. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Moritoh Y; Takeuchi K; Hazama M
J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
[TBL] [Abstract][Full Text] [Related]
9. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Rieg T; Gerasimova M; Murray F; Masuda T; Tang T; Rose M; Drucker DJ; Vallon V
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F963-71. PubMed ID: 22832924
[TBL] [Abstract][Full Text] [Related]
10. Oral Administration of Collagen Hydrolysates Improves Glucose Tolerance in Normal Mice Through GLP-1-Dependent and GLP-1-Independent Mechanisms.
Iba Y; Yokoi K; Eitoku I; Goto M; Koizumi S; Sugihara F; Oyama H; Yoshimoto T
J Med Food; 2016 Sep; 19(9):836-43. PubMed ID: 27540823
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas.
de Heer J; Rasmussen C; Coy DH; Holst JJ
Diabetologia; 2008 Dec; 51(12):2263-70. PubMed ID: 18795252
[TBL] [Abstract][Full Text] [Related]
12. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
13. The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice.
Ørgaard A; Holst JJ
Diabetologia; 2017 Sep; 60(9):1731-1739. PubMed ID: 28551699
[TBL] [Abstract][Full Text] [Related]
14. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
16. Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with
Esser N; Mongovin SM; Parilla J; Barrow BM; Mundinger TO; Fountaine BS; Larmore MJ; Castillo JJ; Akter R; Hull RL; Zraika S
Am J Physiol Endocrinol Metab; 2022 Mar; 322(3):E307-E318. PubMed ID: 35128957
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
Yaribeygi H; Sathyapalan T; Sahebkar A
Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698
[TBL] [Abstract][Full Text] [Related]
18. Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice.
Tudurí E; Beiroa D; Porteiro B; López M; Diéguez C; Nogueiras R
Diabetes Obes Metab; 2015 Aug; 17(8):789-99. PubMed ID: 25962313
[TBL] [Abstract][Full Text] [Related]
19. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
